1352718-88-7 Usage
Molecular weight
330.20
Structure
A pyrrolidine ring with a bromo-imidazole ring attached to position 4, a carboxylic acid group at position 1, and a tert-butyl ester group attached to the carboxylic acid.
Appearance
Not provided in the material.
Solubility
Not provided in the material.
Stability
The presence of the tert-butyl ester group adds stability to the compound.
Lipophilicity
The presence of the tert-butyl ester group increases the lipophilicity of the compound.
Biological activity
Potential biological activity, but further research and testing are necessary to fully understand its properties and potential uses.
Applications
Used in chemical and pharmaceutical research, and has potential applications in the development of new drugs and pharmaceuticals due to its structural features.
Check Digit Verification of cas no
The CAS Registry Mumber 1352718-88-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,2,7,1 and 8 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1352718-88:
(9*1)+(8*3)+(7*5)+(6*2)+(5*7)+(4*1)+(3*8)+(2*8)+(1*8)=167
167 % 10 = 7
So 1352718-88-7 is a valid CAS Registry Number.
1352718-88-7Relevant articles and documents
METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR
-
, (2012/10/08)
Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.
5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS
-
, (2011/06/28)
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Anti-Viral Compounds
-
, (2010/12/29)
Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
